ProKidney (NASDAQ:PROK) and Crinetics Pharmaceuticals (NASDAQ:CRNX) Head-To-Head Survey

ProKidney (NASDAQ:PROK) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Volatility & Risk

ProKidney has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.

Profitability

This table compares ProKidney and Crinetics Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

Valuation and Earnings

This table compares ProKidney and Crinetics Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890,000.00	621.09	-$68.99 million	($0.53)	-3.45
Crinetics Pharmaceuticals	$7.70 million	502.55	-$465.32 million	($5.13)	-7.15

ProKidney has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

51.6% of ProKidney shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProKidney and Crinetics Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2	1	4	1	2.50
Crinetics Pharmaceuticals	1	0	8	1	2.90

ProKidney presently has a consensus price target of $7.40, indicating a potential upside of 304.37%. Crinetics Pharmaceuticals has a consensus price target of $76.13, indicating a potential upside of 107.43%. Given ProKidney’s higher probable upside, research analysts clearly believe ProKidney is more favorable than Crinetics Pharmaceuticals.

Summary

ProKidney beats Crinetics Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.